TECX: Tectonic Therapeutic, Inc.
About
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Current Value
$43.681 Year Return
Current Value
$43.681 Year Return
Key Details
Market Cap
$602.80M
P/E Ratio
-4.2
1Y Stock Return
170.24%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
4.0
Strategies that include TECX
Stock's related to TECX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NNDM | 34.58% | $458.21M | -13.64% | 0.00% |
| CALX | 30.08% | $2.15B | -14.51% | 0.00% |
| CAPR | 28.73% | $839.37M | +532.19% | 0.00% |
| WYNN | 24.72% | $10.02B | +5.05% | 1.10% |
| PRGS | 24.62% | $2.82B | +23.36% | 1.06% |
| SLAB | 23.03% | $3.19B | -2.58% | 0.00% |
| ASH | 23.01% | $3.73B | -1.96% | 2.08% |
| LBRDA | 22.72% | $12.29B | +4.47% | 0.00% |
| IGMS | 22.58% | $567.29M | +67.37% | 0.00% |
| XNET | 22.58% | $123.61M | +26.62% | 0.00% |
| CYRX | 22.15% | $342.80M | -48.82% | 0.00% |
| BABA | 21.77% | $208.58B | +11.29% | 2.30% |
| UPS | 21.57% | $113.67B | -11.06% | 4.89% |
| VYGR | 21.41% | $287.88M | -21.46% | 0.00% |
| CTRN | 21.30% | $153.27M | -29.99% | 0.00% |
| LBRDK | 21.06% | $12.37B | +4.89% | 0.00% |
| TAC | 20.78% | $3.09B | +31.01% | 1.68% |
| NEWT | 20.65% | $364.85M | +5.72% | 5.42% |
| CLFD | 20.55% | $398.66M | +4.48% | 0.00% |
| FLS | 20.48% | $7.89B | +58.40% | 1.38% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| WSO | -<0.01% | $21.53B | +35.75% | 1.97% |
| ACIC | -0.01% | $631.49M | +58.21% | 0.00% |
| MDB | -0.02% | $21.36B | -28.69% | 0.00% |
| SSRM | 0.02% | $1.17B | -48.85% | 0.00% |
| SWI | 0.03% | $2.22B | +22.97% | 0.00% |
| VITL | -0.03% | $1.32B | +142.79% | 0.00% |
| PPC | 0.04% | $12.38B | +100.96% | 0.00% |
| WHD | -0.05% | $4.35B | +56.25% | 0.75% |
| TRV | -0.06% | $58.86B | +48.10% | 1.59% |
| ELAN | -0.06% | $6.58B | +12.99% | 0.00% |
| SJM | -0.06% | $11.91B | -0.25% | 3.82% |
| LITB | -0.07% | $35.48M | -75.45% | 0.00% |
| AHCO | -0.07% | $1.31B | +17.07% | 0.00% |
| FCFS | 0.08% | $4.70B | -6.20% | 1.39% |
| WTW | 0.09% | $30.98B | +26.60% | 1.13% |
| BAH | -0.10% | $17.62B | +9.13% | 1.47% |
| BOOM | 0.10% | $151.20M | -52.25% | 0.00% |
| GEO | 0.11% | $3.97B | +204.07% | 0.00% |
| ARHS | -0.11% | $1.30B | +6.48% | 0.00% |
| ANAB | 0.12% | $607.66M | +40.93% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SANM | -12.71% | $4.20B | +56.10% | 0.00% |
| PULM | -12.51% | $19.83M | +202.98% | 0.00% |
| VIRT | -12.27% | $3.17B | +110.38% | 2.60% |
| GPN | -11.23% | $29.20B | +2.38% | 0.87% |
| DLNG | -10.90% | $161.93M | +73.23% | 0.00% |
| FTRE | -10.17% | $1.68B | -42.77% | 0.00% |
| TH | -9.96% | $839.02M | -24.49% | 0.00% |
| V | -9.84% | $595.29B | +23.64% | 0.69% |
| HSY | -9.69% | $34.45B | -10.68% | 3.21% |
| TEO | -9.68% | $1.69B | +87.97% | 0.00% |
| CBOE | -9.37% | $21.46B | +15.84% | 1.11% |
| NINE | -9.20% | $49.99M | -42.44% | 0.00% |
| HLN | -8.91% | $42.91B | +13.94% | 1.67% |
| GLP | -8.84% | $1.77B | +51.33% | 5.50% |
| PG | -8.82% | $402.15B | +14.14% | 2.33% |
| EOG | -8.44% | $76.03B | +10.19% | 2.70% |
| CIG.C | -8.42% | $2.48B | -3.55% | 0.00% |
| CPRI | -8.24% | $2.36B | -58.95% | 0.00% |
| SITC | -8.23% | $847.27M | +59.73% | 2.42% |
| MDLZ | -8.21% | $85.41B | -10.00% | 2.73% |
ETF's related to TECX
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IBDV | 0.05% | $1.39B | 0.1% |
| BOND | 0.05% | $5.01B | 0.58% |
| USTB | 0.07% | $797.28M | 0.35% |
| IBDS | -0.08% | $2.63B | 0.1% |
| FISR | 0.08% | $307.49M | 0.5% |
| OVT | 0.10% | $45.27M | 0.85% |
| KCCA | -0.10% | $220.51M | 0.87% |
| OWNS | 0.15% | $124.17M | 0.3% |
| IBD | 0.16% | $330.68M | 0.44% |
| FBY | -0.16% | $127.69M | 0.99% |
| PFFV | 0.18% | $257.84M | 0.25% |
| CGCB | -0.18% | $1.49B | 0.27% |
| SUSB | 0.20% | $959.94M | 0.12% |
| IBMM | -0.20% | $391.28M | 0.18% |
| IBTG | 0.21% | $1.48B | 0.07% |
| IBDU | 0.24% | $1.95B | 0.1% |
| DFSD | 0.25% | $3.63B | 0.16% |
| LQDW | -0.30% | $206.97M | 0.34% |
| BYLD | 0.31% | $232.64M | 0.15% |
| IYK | -0.32% | $1.30B | 0.4% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -15.46% | $388.04M | 1.43% |
| TAIL | -13.88% | $67.98M | 0.59% |
| GRNB | -12.17% | $107.41M | 0.2% |
| TPMN | -11.67% | $40.60M | 0.65% |
| AGGY | -10.66% | $926.64M | 0.12% |
| FMB | -10.55% | $2.03B | 0.65% |
| VIXY | -10.41% | $195.31M | 0.85% |
| SCHO | -9.30% | $11.10B | 0.03% |
| IBTE | -8.95% | $1.70B | 0.07% |
| VGLT | -8.92% | $12.70B | 0.04% |
| GOVZ | -8.87% | $313.00M | 0.1% |
| EDV | -8.78% | $3.88B | 0.06% |
| SOYB | -8.76% | $27.32M | 0.22% |
| SCHQ | -8.73% | $762.08M | 0.03% |
| AGZ | -8.66% | $708.37M | 0.2% |
| TOTL | -8.63% | $3.31B | 0.55% |
| ZROZ | -8.63% | $1.63B | 0.15% |
| GOVI | -8.57% | $1.06B | 0.15% |
| FLDR | -8.20% | $595.01M | 0.15% |
| HTAB | -8.08% | $437.10M | 0.4% |
News
Yahoo
Tectonic Therapeutic Inc ( (TECX) ) has released its Q3 earnings. Here is a breakdown of the information Tectonic Therapeutic Inc presented to its investors. Tectonic Therapeutic Inc., based in Watertown, Massachusetts, is a clinical-stage biotechnology company specializing in the development of therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs) to address unmet medical needs. Tectonic recently announced its third-quarter 2024 financial results, highlighting signif
Yahoo
Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal plasma flow (“RPF”)TX45 showed a favorable safety profile, with no observed injection site reactions, immunogenicity, or detection of anti-drug antibodiesRPF-based exposure-response model enabled APEX Phase 2 dose selectionUpcoming topline results from the ongoing TX45 clinical program includes Phase 1b hemodyna
Yahoo
Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early Q2’2025First subject dosed with TX000045 (“TX45”) in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 (“TX2100”) selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to p
Yahoo
Tectonic Therapeutic, Inc. ( NASDAQ:TECX ) shareholders (or potential shareholders) will be happy to see that the...
Yahoo
American Heart Association (AHA) poster to be presented on November 16, 2024WATERTOWN, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced that it will present a poster at AHA 2024 highlighting Phase 1a data for its lead asset TX000045 (“TX45”), a long-
SeekingAlpha
Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension. Read why I think TECX stock is a buy.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.